Company Overview Summary

Company Name

Connect Biopharma Holdings Limited

Legal & Corporate Details

• Incorporated in the Cayman Islands as an exempted company
• Foreign private issuer under Rule 3b-4 of the Securities Exchange Act of 1934
• Headquartered in San Diego, California
• Principal offices located at 3580 Carmel Mountain Road, Suite 200, San Diego, CA 92130
• Phone: (858) 727-1040
• Website: www.connectbiopharm.com
• Traded on Nasdaq Global Market under the symbol CNTB

Business Focus

• Biopharmaceutical company at the clinical development stage
• Focused on advancing rademikibart, a next-generation anti-IL-4Rα monoclonal antibody
• Rademikibart targets treatments for asthma and chronic obstructive pulmonary disease (COPD)
• Aims to treat acute exacerbations of respiratory diseases and chronic conditions driven by Type 2 inflammation

Product Pipeline

• Currently has one product candidate in clinical development: rademikibart
• Rademikibart is designed to block IL-4 and IL-13 signaling by targeting IL-4Rα
• Demonstrates rapid onset (within 24 hours) and potential for improved efficacy and safety compared to existing treatments
• In Phase 2b global asthma trial (CBP-201-WW002) with positive preliminary results
• Completed Phase 2 trials for atopic dermatitis in China and other regions, but not pursuing further development in AD at present

Market & Commercial Strategy

• No current revenue or earnings reported
• Focused on clinical trials to eventually seek regulatory approvals for rademikibart
• Engaged in licensing and collaborations, including a key agreement with Simcere Pharma for development and commercialization in Greater China
• As of December 31, 2024:
  • Received $21 million upfront from collaborations
  • Earned $5.9 million from milestones and cost reimbursements
• About 55.3 million ordinary shares outstanding as of March 21, 2025

Employees

• Total employees: 62
  • Research & Development: 35
  • Administrative & Corporate Functions: 27

Revenue & Income

• Net losses:
  • $15.6 million for the year ending December 31, 2024
  • $62.1 million for the year ending December 31, 2023
• Total accumulated losses as of December 31, 2024: $345.4 million

Summary

Connect Biopharma is a clinical-stage biopharmaceutical company developing antibody therapies for respiratory and inflammatory diseases, primarily focusing on rademikibart for treating asthma and COPD. It has no current commercial products or revenue, is actively conducting clinical trials, and has partnerships in place for development in China. The company has 62 employees and reported a net loss of $15.6 million in 2024, with total accumulated losses of $345.4 million.